TAVNEOS
Drug
Amgen Inc.
Total Payments
$9.0M
Transactions
31,926
Doctors
8,964
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $6.5M | 18,895 | 6,985 |
| 2023 | $2.4M | 11,539 | 4,586 |
| 2022 | $36,957 | 1,492 | 1,152 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.3M | 113 | 59.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.1M | 1,136 | 23.0% |
| Food and Beverage | $840,399 | 28,987 | 9.4% |
| Consulting Fee | $414,814 | 285 | 4.6% |
| Travel and Lodging | $322,266 | 1,011 | 3.6% |
| Education | $21,586 | 389 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $12,450 | 5 | 0.1% |
Payments by Type
Research
$5.3M
113 transactions
General
$3.7M
31,813 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Ph4 PMR Avacopan in subjects with ANCA-associated vasculitis CL018_168 | Amgen Inc. | $2.8M | 0 |
| Renal Impairment PK study | Amgen Inc. | $743,213 | 0 |
| Treatment response in MGH AAV registry | Amgen Inc. | $635,968 | 0 |
| Ph4 PMR Avacopan in subjects with ANCA-associated vasculitis (CL018_168 ) | Amgen Inc. | $612,000 | 0 |
| Ph3 Avacopan in peds with ANCA-associated vasculitis | Amgen Inc. | $320,746 | 0 |
| Ph3 Avacopan in subjects with ANCA-associated vasculitis pivotal study ADVOCATE | Amgen Inc. | $74,552 | 6 |
| Ph2 Avacopan in adult and adolescent 12-17 subjects with C3G | Amgen Inc. | $29,414 | 1 |
| AAV trtmnt resp with MGH COLLAB | Amgen Inc. | $17,950 | 0 |
| Pt char & outcomes in TAVNEOS users | Amgen Inc. | $7,587 | 3 |
| Food Effect and Pharmacokinetic Bridging of Avacopan in Caucasian and Japanese Healthy Subjects | Amgen Inc. | $3,291 | 1 |
| A phase I thorough QT/QTc study evaluating therapeutic and supratherapeutic doses of avacopan in healthy participants | Amgen Inc. | $1,037 | 1 |
| Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants | Amgen Inc. | $355.11 | 1 |
Top Doctors Receiving Payments for TAVNEOS — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Rheumatology | Beverly Hills, CA | $5,117 | 10 |
| , MD | Rheumatology | Cincinnati, OH | $5,036 | 7 |
| , A.P.N.P | Rheumatology | Franklin, WI | $4,757 | 30 |
| , M.D | Rheumatology | Skokie, IL | $4,700 | 39 |
| , M.D | Family Medicine | Tempe, AZ | $4,683 | 3 |
| , MD | Rheumatology | Bothell, WA | $4,673 | 14 |
| , MD FACP FACR | Rheumatology | Tacoma, WA | $4,336 | 6 |
| , M.D | Otolaryngology | Saint Louis, MO | $4,252 | 4 |
| , MD | Student in an Organized Health Care Education/Training Program | Old Saybrook, CT | $4,100 | 3 |
| , MD | Rheumatology | Charlotte, NC | $3,972 | 14 |
| , MD | Nephrology | Richmond, VA | $3,942 | 2 |
| , MD | Surgery | Columbus, OH | $3,861 | 2 |
| , M.D | Rheumatology | Dallas, TX | $3,550 | 8 |
| , MD | Nephrology | Denver, CO | $3,487 | 9 |
| , MD | Rheumatology | Kansas City, MO | $3,484 | 12 |
| , MD | Hospitalist | Great Falls, MT | $3,314 | 10 |
| , MD | Nephrology | Boston, MA | $3,285 | 2 |
| , MD | Student in an Organized Health Care Education/Training Program | Chicago, IL | $3,111 | 5 |
| , M.D | Nephrology | Lawrenceville, GA | $2,892 | 5 |
| , M.D | Student in an Organized Health Care Education/Training Program | Sugar Land, TX | $2,884 | 19 |
| , M.D | Internal Medicine | Chicago, IL | $2,827 | 4 |
| , M.D | Student in an Organized Health Care Education/Training Program | Philadelphia, PA | $2,752 | 4 |
| , DO | Specialist | Charleston, SC | $2,642 | 5 |
| , MD | Rheumatology | Carthage, MO | $2,538 | 3 |
| , MD, MBA | Pulmonary Disease | Los Angeles, CA | $2,500 | 2 |
Ad
Manufacturing Companies
- Amgen Inc. $9.0M
Product Information
- Type Drug
- Total Payments $9.0M
- Total Doctors 8,964
- Transactions 31,926
About TAVNEOS
TAVNEOS is a drug associated with $9.0M in payments to 8,964 healthcare providers, recorded across 31,926 transactions in the CMS Open Payments database. The primary manufacturer is Amgen Inc..
Payment data is available from 2022 to 2024. In 2024, $6.5M was paid across 18,895 transactions to 6,985 doctors.
The most common payment nature for TAVNEOS is "Unspecified" ($5.3M, 59.0% of total).
TAVNEOS is associated with 12 research studies, including "Ph4 PMR Avacopan in subjects with ANCA-associated vasculitis CL018_168" ($2.8M).